The Department of Health has asked the Institute to conduct an appraisal of rociletinib for previously treated locally advanced or metastatic, EGFR T790M -positive non-small-cell lung cancer.
We have now been informed by the company that it will no longer be pursuing a licensing application , therefore, NICE has decided to suspend this appraisal on its current work programme.
As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.
|Evidence Review Group / Assessment Group
||Liverpool Reviews and Implementation Group, University of Liverpool